Conmed (CNMD) Stock Forecast & Price Target

Compare

201 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CNMD Analyst Ratings

Hold

1 Buy

3 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Conmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CNMD Stock 12 Month Forecast

Average Price Target

$53.00

▲(19.50% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Conmed in the last 3 months. The average price target is $53.00 with a high forecast of $55.00 and a low forecast of $52.00. The average price target represents a 19.50% change from the last price of $44.35.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","51":"$51","59":"$59","67":"$67","75":"$75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$53.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$52.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,51,59,67,75],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.5,45.30769230769231,46.11538461538461,46.92307692307692,47.73076923076923,48.53846153846154,49.34615384615385,50.15384615384615,50.96153846153846,51.76923076923077,52.57692307692308,53.38461538461539,54.19230769230769,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.5,45.15384615384615,45.80769230769231,46.46153846153846,47.11538461538461,47.76923076923077,48.42307692307692,49.07692307692308,49.73076923076923,50.38461538461539,51.03846153846154,51.69230769230769,52.34615384615385,{"y":53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.5,45.07692307692308,45.65384615384615,46.23076923076923,46.80769230769231,47.38461538461539,47.96153846153846,48.53846153846154,49.11538461538461,49.69230769230769,50.26923076923077,50.84615384615385,51.42307692307692,{"y":52,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":69.44,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.924,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.004,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.766,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.969,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.865,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.092,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.154,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$55.00

Average Price Target$53.00

Lowest Price Target$52.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Matson

Needham

Hold

―

Reiterated

01/09/26

Analysts Offer Insights on Healthcare Companies: Alcon (NYSE: ALC), AbSci (NASDAQ: ABSI) and Conmed (NYSE: CNMD)

Matthew O'Brien

Piper Sandler

$55

Buy

24.01%

Upside

Reiterated

01/09/26

Piper Sandler Sticks to Their Buy Rating for Conmed (CNMD)

Travis Steed

Bank of America Securities

$52

Hold

17.25%

Upside

Reiterated

12/08/25

Conmed's Strategic Exit from Gastroenterology: Hold Rating Amid Portfolio Optimization and Financial Adjustments

Robbie Marcus

J.P. Morgan

$58→$52

Hold

17.25%

Upside

Reiterated

11/06/25

Conmed price target lowered to $52 from $58 at JPMorganConmed price target lowered to $52 from $58 at JPMorgan

Unknown Analyst

Jefferies

Not Ranked

Jefferies

Hold

―

Reiterated

05/02/25

We maintain our Hold rating on CNMD.

Rick Wise

Stifel Nicolaus

$55

Hold

24.01%

Upside

Reiterated

05/01/25

Stifel Nicolaus Reaffirms Their Hold Rating on Conmed (CNMD)

Vik Chopra

Wells Fargo

$70→$57

Hold

28.52%

Upside

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and Conmed (NYSE: CNMD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Matson

Needham

Hold

―

Reiterated

01/09/26

Analysts Offer Insights on Healthcare Companies: Alcon (NYSE: ALC), AbSci (NASDAQ: ABSI) and Conmed (NYSE: CNMD)

Matthew O'Brien

Piper Sandler

$55

Buy

24.01%

Upside

Reiterated

01/09/26

Piper Sandler Sticks to Their Buy Rating for Conmed (CNMD)

Travis Steed

Bank of America Securities

$52

Hold

17.25%

Upside

Reiterated

12/08/25

Conmed's Strategic Exit from Gastroenterology: Hold Rating Amid Portfolio Optimization and Financial Adjustments

Robbie Marcus

J.P. Morgan

$58→$52

Hold

17.25%

Upside

Reiterated

11/06/25

Conmed price target lowered to $52 from $58 at JPMorganConmed price target lowered to $52 from $58 at JPMorgan

Unknown Analyst

Jefferies

Not Ranked

Jefferies

Hold

―

Reiterated

05/02/25

We maintain our Hold rating on CNMD.

Rick Wise

Stifel Nicolaus

$55

Hold

24.01%

Upside

Reiterated

05/01/25

Stifel Nicolaus Reaffirms Their Hold Rating on Conmed (CNMD)

Vik Chopra

Wells Fargo

$70→$57

Hold

28.52%

Upside

Reiterated

04/30/25

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and Conmed (NYSE: CNMD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Conmed

1 Month

xxx

Success Rate

6/20 ratings generated profit

Average Return

-1.65%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 30.00% of your transactions generating a profit, with an average return of -1.65% per trade.

3 Months

xxx

Success Rate

6/20 ratings generated profit

Average Return

-4.66%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 30.00% of your transactions generating a profit, with an average return of -4.66% per trade.

1 Year

Matthew O'BrienPiper Sandler

Success Rate

4/20 ratings generated profit

Average Return

-16.74%

reiterated a buy rating 2 days ago

Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -16.74% per trade.

2 Years

xxx

Success Rate

0/20 ratings generated profit

Average Return

-32.06%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -32.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CNMD Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CNMD has received 3 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. CNMD average Analyst price target in the past 3 months is 53.00.

Each month's total comprises the sum of three months' worth of ratings.

CNMD Financial Forecast

CNMD Earnings Forecast

Next quarter’s earnings estimate for CNMD is $1.32 with a range of $1.31 to $1.33. The previous quarter’s EPS was $1.08. CNMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CNMD has Performed in-line its overall industry.

CNMD Sales Forecast

Next quarter’s sales forecast for CNMD is $366.96M with a range of $365.94M to $368.50M. The previous quarter’s sales results were $338.58M. CNMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CNMD has Performed in-line its overall industry.

CNMD Stock Forecast FAQ

What is CNMD’s average 12-month price target, according to analysts?

Based on analyst ratings, Conmed’s 12-month average price target is 53.00.

What is CNMD’s upside potential, based on the analysts’ average price target?

Conmed has 19.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CNMD a Buy, Sell or Hold?

Conmed has a consensus rating of Hold which is based on 1 buy ratings, 3 hold ratings and 0 sell ratings.

What is Conmed’s price target?

The average price target for Conmed is 53.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.00 ,the lowest forecast is $52.00. The average price target represents 19.50% Increase from the current price of $44.35.

What do analysts say about Conmed?

Conmed’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of CNMD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Conmed (CNMD) Stock Forecast & Price Target

CNMD Analyst Ratings

CNMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Conmed

CNMD Analyst Recommendation Trends

CNMD Financial Forecast

CNMD Earnings Forecast

CNMD Sales Forecast

CNMD Stock Forecast FAQ

Detailed List of Analyst Forecasts